BITA JALILIZEINALI: Open Payments
NPI 1710006275 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,364 in 36 payments from 20 companies in 2025. Trend: 2023 $661 · 2024 $1,090 · 2025 $1,364
Food & beverage: $1,264Education: $100
| Company | Payments | Amount |
|---|---|---|
| SANOFI-AVENTIS U.S. LLC | 4 | $178 |
| Janssen Biotech, Inc. | 2 | $140 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| Gamida Cell Inc. | 3 | $120 |
| BeOne Medicines USA, Inc. | 1 | $112 |
| Incyte Corporation | 3 | $84 |
| SOBI, INC | 3 | $77 |
| AstraZeneca Pharmaceuticals LP | 2 | $64 |
| Syndax Pharmaceuticals, Inc. | 2 | $59 |
| Gilead Sciences, Inc. | 1 | $56 |
Products named: REZUROCK, REBLOZYL, OMISIRGE, RYBREVANT, BRUKINSA, Vonjo, REVUFORJ, Yescarta.
Industry payments across NY — which companies pay providers there.
